News

Filter

Current filters:

LicensingEli Lilly

1 to 9 of 29 results

UPDATE: Lilly rekindles deal with Adocia to develop ultra rapid insulin

UPDATE: Lilly rekindles deal with Adocia to develop ultra rapid insulin

19-12-2014

US pharma major Eli Lilly and French biotech firm Adocia have entered into a worldwide licensing collaboration…

AdociaBioChaperone LisproBiotechnologyDiabetesEli LillyGlobalLicensing

Lilly in-licenses Zosano’s osteo patch for up to $440 million

03-12-2014

Privately-held US biotech firm Zosano Pharma has entered into an exclusive agreement with pharma major…

Anti-Arthritics/RheumaticsBiotechnologyEli LillyLicensingZosano PharmaZP-PTH

Boehringer Ingelheim and Lilly revise diabetes alliance in certain countries

29-10-2014

In a move that will strengthen their 2011 alliance by enhancing efficiencies and enabling greater focus…

Boehringer IngelheimDiabetesEli LillyJardianceJentaduetoLicensingMarkets & MarketingPharmaceuticalTrajenta

Lilly expands collaboration with Zymeworks

Lilly expands collaboration with Zymeworks

23-10-2014

US pharma major Eli Lilly and privately-held Canadian biotech firm Zymeworks have expanded their existing…

CanadaEli LillyLicensingOncologyPharmaceuticalResearchUSAZymeworks

Stada Arz in-licenses teriparatide, expanding its biosimilars portfolio

Stada Arz in-licenses teriparatide, expanding its biosimilars portfolio

13-10-2014

German generic and branded drugmaker Stada Arzneimittel has in-licensed osteoporosis drug teriparatide,…

Anti-Arthritics/RheumaticsBiosimilarsEli LillyForsteoGenericsLicensingRichter-Helm BioTecSTADA Arzneimittelteriparatide

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

Pharma partnerships vital in stagnant Alzheimer’s treatment market, says analyst

24-09-2014

US pharma major Eli Lilly’s recent partnership with Anglo-Swedish peer AstraZeneca to develop oral…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearch

Denovo Biopharma acquires Lilly’s enzastaurin for development as a personalized medicine

Denovo Biopharma acquires Lilly’s enzastaurin for development as a personalized medicine

17-09-2014

Privately-held San Diego, USA-based biotech firm Denovo Biopharma has acquired enzastaurin, a late-stage…

BiotechnologyDenovo BiopharmaEli LillyenzastaurinGlobalLicensingOncology

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

Lilly to pay up to $500 million for AstraZeneca Alzheimer’s candidate

16-09-2014

Anglo-Swedish pharma major AstraZeneca and US peer Eli Lilly have entered an agreement to jointly develop…

AstraZenecaAZD3293Eli LillyLicensingNeurologicalPharmaceuticalResearchUKUSA

1 to 9 of 29 results

COMPANY SPOTLIGHT

Menarini

Back to top